Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lung Cancer

Title: Lung cancer (Amsterdam, Netherlands)

Publisher: Elsevier BV

ISSN (Electronic): 1872-8332

ISSN (Print): 0169-5002

Publication date (Electronic): May 2016

Volume: 95

Affiliations

[1 ] Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany.

[2 ] Department of Dermatology, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany.

[3 ] Institute of Pathology, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany.

[4 ] Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany. Electronic address: Wolfgang.brueckl@klinikum-nuernberg.de.

Article

Publisher Item ID: S0169-5002(16)30231-8

DOI: 10.1016/j.lungcan.2016.02.015

PubMed ID: 27040849

SO-VID: ba295ca4-3327-480f-aa73-f2d77bacf5d2

History

Keywords: NSCLC,SJS,TKI,Afatinib

Data availability:

Keywords: NSCLC, SJS, TKI, Afatinib

Comments

Comment on this article

scite_

Cited by 15

See all cited by

- Version 1